基于免疫节点抑制剂的肝细胞癌免疫联合治疗多学科中国专家共识(2021版)

Chinese multidisciplinary expert consensus on combined immunotherapy based on immune checkpoint inhibitors for hepatocellular carcinoma(2021 version)

基于免疫节点抑制剂(ICIs)的肝癌免疫联合治疗在临床研究和临床实践中已取得了显著的疗效,但在临床推广普及的过程中也发现了许多亟待解决的问题。通过多学科专家的共同研讨,《基于免疫节点抑制剂的HCC免疫联合治疗多学科中国专家共识(2021版)》主要聚焦于ICIs疗法临床应用的原则与方法,包括适应证选择、药物处方、治疗方式选择、疗程及不良反应的监测与管理和疗效的评估等方面。共识旨在结合最新研究进展和专家经验总结归纳出翔实的临床应用细则,为专业人员提供参考。

Combined immunotherapy based on immune checkpoint inhibitors(ICIs)for hepatocellular carcinoma has achieved remarkable therapeutic effects in clinical research and practice.However,many problems that need to be resolved have also been recognized in the clinical promotion process.Therefore,the primary effort through the multidisciplinary experts'mutual discussion[Chinese multidisciplinary expert consensus on combined immunotherapy based on immune check point inhibitors for hepatocellular carcinoma(2021 version)]is to implement the principles and methods of clinical application of ICIs treatment,including the selection of indica-tions,prescriptions,treatment methods,monitoring and management of treatment process and adverse reactions,and efficacy evaluation.In addition,the consensus aims to combine the latest research progress,summarize detailed clinical application rules and expert experience,so as to provide reference for health professionals.